Document is current
Any future updates will be listed below
-
Authors
Su, Chang https://orcid.org/0000-0003-4019-6389
Hou, Yu
Xu, Jielin
Xu, Zhenxing
Zhou, Manqi
Ke, Alison
Li, Haoyang
Xu, Jie
Brendel, Matthew https://orcid.org/0000-0003-3417-4597
Maasch, Jacqueline R. M. A.
Bai, Zilong
Zhang, Haotan
Zhu, Yingying
Cincotta, Molly C.
Shi, Xinghua
Henchcliffe, Claire https://orcid.org/0000-0002-0899-3030
Leverenz, James B. https://orcid.org/0000-0002-0896-0749
Cummings, Jeffrey
Okun, Michael S. https://orcid.org/0000-0002-6247-9358
Bian, Jiang https://orcid.org/0000-0002-2238-5429
Cheng, Feixiong https://orcid.org/0000-0002-1736-2847
Wang, Fei https://orcid.org/0000-0001-9459-9461
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (MJFF-023081, MJFF-023081)
Foundation for the National Institutes of Health (R01AG080991, R01AG076234, RF1AG072449, R01AG076448, P20GM109025, U01NS093334, R01AG053798, P30AG072959, R35AG71476, AG083721-01, R01AG076234, R01AG080991, R01AG076448, U01AG073323, R21AG083003, R01AG066707, R01AG082118, RF1AG082211, RF1NS133812, 3R01AG066707-01S1, 3R01AG066707-02S1, R56AG074001)
Michael J. Fox Foundation for Parkinson's Research
Alzheimer’s Disease Drug Discovery Foundation (ADDF); Ted and Maria Quirk Endowment; Joy Chambers-Grundy Endowment
Alzheimer's Association (ALZDISCOVERY-1051936)
- License Information
-
More Information
Article History
Received: 24 December 2023
Accepted: 21 June 2024
First Online: 9 July 2024
Competing interests
: J.C. has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. The other authors declare no Competing Financial or Non-Financial Interests.
